Nektar Therapeutics (NKTR NASDAQ) stock market data APIs
$57.1685
1.8(3.1%)
as of November 12, 2025
Try our APIs with
free plan!
Nektar Therapeutics Financial Data Overview
Price chart is built with
Anychart
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Prev. Close
57.1685
Open
58.9711
High
59.0343
Low
56.6643
52 wk Range
6.45-66.92
Market Cap
1 173 M
Shares Outstanding
20 342 K
Revenue
62 600 K
EPS
-1.8675
Beta
1.282
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Nektar Therapeutics (top by weight)
Ticker
100-day Price Change
Weight
POAGX.US
PRIMECAP ODYSSEY AGGRESSIVE GROWTH FUND PRIMECAP ODYSSEY AGGRESSIVE GROWTH FUND
9.28
(19.8%)
5.33
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nektar Therapeutics data using free add-ons & libraries
Get Nektar Therapeutics Fundamental Data
Nektar Therapeutics Fundamental data includes:
- Net Revenue: 62 600 K
- EBITDA: -135 388 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-07
- EPS/Forecast: -2.7887
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nektar Therapeutics News
New
Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine
Turn Therapeutics Turn’s Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee Therapeutics, and Nektar Therapeutics LOS ANGELES, Nov. 11,...
Nektar outlines $1B market opportunity for REZPEG in alopecia areata as Phase III plans advance
Earnings Call Insights: Nektar Therapeutics (NKTR) Q3 2025 MANAGEMENT VIEW * CEO Howard W. Robin welcomed Dr. Mary Tagliaferri back as Chief Medical Officer, noting her previous role in the succes...
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
Nektar Therapeutics NKTR reported a loss of $1.87 per share for the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $2.85. In the year-ago quarter, the company had repor...
Nektar Therapeutics (NKTR) Reports Q3 Loss, Beats Revenue Estimates
Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $2.85. This compares to a loss of $2.7 per share a year ago. These figures...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
